For healthcare providers and pharmaceutical companies looking for valuable insights into red blood cell health to tackle conditions like sick cell disease, Functional Fluidics (313-315-2555) is it. With their highly reliable proprietary diagnostic platforms and biomarkers, they’re on their way to becoming the gold standard.
Red blood cells play a vital role in keeping our heart pumping and brain running.
They carry oxygen from our lungs to tissues throughout our body and bring carbon dioxide back to the lungs so it can be exhaled. Essentially, keeping these bright red cells healthy and in their plentiful state is imperative. Unfortunately, despite their importance, scientists are still trying to decipher many aspects of red blood cell health and production.
Detroit-based Functional Fluidics is working to change this. One of its provisions is offering in-depth insights into the health of red blood cells via its testing platforms that assess key properties supporting red blood cell function and survival, helping to advance drug development and patient care for sickle cell disease (SCD).
Now, the biotech company is spreading its operations to sub-Saharan Africa, starting with Nigeria, with the aim of increasing local access to its diagnostic tools, thereby increasing the number of sickle cell patients who can receive proper care for their condition.
Head to https://www.functionalfluidics.com for more information.
Sickle cell disease is a group of inherited disorders that affect the hemoglobin and causes an individual’s red blood cells, which transport oxygen throughout the body, to become curved like a sickle or crescent moon, sticky, and stiff instead of round and flexible. Due to this, blood flow in people with the disease can become slowed or blocked, leading to anemia, pain, infections, or organ damage.
According to the World Health Organization, about 5% of the world’s population carries trait genes for hemoglobin disorders such as sickle cell disease, with over 300,000 babies being born each year with severe hemoglobin disorders. And with approximately 80% of sickle-cell cases occurring in sub-Saharan Africa, the region has the highest prevalence of individuals living with the disease.
Founded in 2014, Functional Fluidics specializes in clinical blood function assessments to evaluate individual patient responses. Since its establishment, the company has been providing clinically-validated assays to healthcare providers and pharmaceutical companies across the United States.
Its diagnostic platforms evaluate the health of red blood cells in the body by replicating their environment during studies. Through these tests, specific issues related to the health of red blood cells are assessed and identified.
The company then provides the collated information to doctors and scientists, allowing them to develop requisite drug therapies and help providers caring for patients with sickle cell disease. The biotech company also supplies monitoring services for clinical studies, using its assays to measure the effects of a drug on blood function.
With reliable assays — which integrate clinical trial support, deep scientific knowledge, laboratory expertise, and data sciences — Functional Fluidics seeks to help develop transformative drug therapies faster and more cost-effectively to aid sickle-cell patients in sub-Saharan Africa.
“We are committed to expanding access to valuable insights on the health of red blood cells that can be obtained from our portfolio of red blood cell biomarkers. Our goal at Functional Fluidics is to help Life Science innovators accelerate the speed, cost, and success rate of bringing new life-changing therapies to individuals with sickle cell disease,” said Dr. Patrick Hines, founder and CEO of Functional Fluidics.
Want to learn more? Visit https://www.functionalfluidics.com and peruse their work as they endeavor to become the gold standard in red blood cell health.
